Superior vena cava syndrome: endovascular management

Karakhanian, Walter Khegan; Belczak, Sérgio Quilici

doi:10.1590/1677-5449.180062

Cited by 9 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our patient's survival time was 7 months. that is in line with endovascular management of SVCS of Vascular and Endovascular Surgery Service of Brazilian University hospital where they managed 28 patients between 2002 and 2012 (11).…”

Section: Discussionsupporting

confidence: 62%

“…This type of recanalization provides immediate symptomatic relief of vein thrombosis in patients with a terminal stadium of the disease (6,7,10,11). At the terminal stage the survival time ranges from 3 to 6 months (10,11). Our patient's survival time was 7 months.…”

Section: Discussionmentioning

confidence: 70%

“…The endovenous treatment of SVC with stent placement is used in case of life-threatening symptoms. This type of recanalization provides immediate symptomatic relief of vein thrombosis in patients with a terminal stadium of the disease (6,7,10,11). At the terminal stage the survival time ranges from 3 to 6 months (10,11).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Tumor mass in the lung with superior vena cava syndrome

et al. 2022

View full text Add to dashboard Cite

Group of symptoms due to vena cava superior obstruction is named superior vena cava syndrome. A 65-year-old female, long-standing smoker was presented with a two-week history of dry cough and facial swelling. The patient noticed a palpable mass on the right side of the neck. Computer tomography scan with contrast showed extensive, irregular, non-homogenous consolidation in the right upper lobe, involving the right hilus, surrounding the aortic arch, supra aortic branches and pleural effusion at the right side of the body. Also, ultrasound examination of supra clavicular space showed enlarged pathologic hypoehogenic lymph node without an echogenic hilum. Ultrasound guided fine needle biopsy of lymph node was performed, and cytopathology findings showed metastatic lesion from primary microcellular lung cancer, IIIC stadium, cT4N3M0. Venous angioplasty was performed showing stenosis in the superior vena cava (the first type of Stanford classification). After balloon dilatation, the stent was placed at the site of stenosis. The patient received chemio- and radiotherapy and survival time was seven months. Superior vena cava syndrome is an urgent clinical condition, and lung cancer is the leading cause of this syndrome. Computer tomography imaging findings and endovascular stent placement are important for detection and management of the superior vena cava thrombosis.

show abstract

Section: Discussionsupporting

confidence: 62%

Section: Discussionmentioning

confidence: 70%

See 1 more Smart Citation

Tumor mass in the lung with superior vena cava syndrome

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Despite its poor efficacy, stent placement, which had the advantage of quickly relieving symptoms, is currently considered to be the first-line treatment (6). It was reported that 90% of patients who underwent stent placement show evident clinical improvement in 24 to 48 hours (7). However, stent placement also has complications such as stent displacement, obstruction, and pericardial tamponade.…”

Section: Discussionmentioning

confidence: 99%

Sintilimab plus chemotherapy achieved symptom relief in stage IV lung squamous cell carcinoma with superior vena cava syndrome: a case report

Guo¹,

Qu²,

Wei³

et al. 2022

Ann Palliat Med

View full text Add to dashboard Cite

Lung cancer is the second most common and mortality disease in the world. Most patients with lung cancer are already at the advanced stage when diagnosed. There are multiple treatments for advanced lung cancer. Among them, immunotherapy plus chemotherapy has gradually become the first-line treatment.Lung cancer has multiple complications, superior vena cava syndrome (SVCS) is a common complication of patients with advanced lung cancer. The current treatments include radiotherapy, chemotherapy, and stent implantation. Stent implantation has the disadvantages of invasiveness and poor efficacy. Immunotherapy, as an emerging treatment for tumors, has shown significant advantages in treating patients with advanced lung cancer. However, the treatment of advanced lung cancer with SVCS using immunotherapy has rarely been reported. Here, we reported a 48-year-old male patient with stage IV (T4N3M1) lung squamous cell carcinoma. After receiving 1 cycle (3 weeks) of comprehensive treatment with sintilimab plus chemotherapy, the tumor mass shrank by 30% to achieve partial response (PR), collateral circulation was formed, and most of the symptoms caused by SVCS disappeared. After 3 cycles of treatment, the tumor shrank by nearly 90%, and the superior and inferior vena cava opened larger than before. Our case provides a novel treatment strategy for such patients.

show abstract

“…Superior vena cava syndrome (SVCS) is a generic term for a syndrome in which compression or obstruction of the SVC impairs the return of venous blood to the heart and causes venous depression in the head, neck, chest, and upper limbs [2]. In the etiology of SVCS, most cases (85%) occur in the presence of malignant disease, particularly bronchogenic carcinomas, lymphomas and metastatic tumors [3]. We experienced a case of SVCS due to mediastinum lymph node metastasis and report the clinical findings, images, cytology, treatment, progress and various considerations.…”

Section: Introductionmentioning

confidence: 99%